About: Broad-spectrum antiviral agents: secreted phospholipase A(2) targets viral envelope lipid bilayers derived from the endoplasmic reticulum membrane

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Broad-spectrum antiviral agents: secreted phospholipase A(2) targets viral envelope lipid bilayers derived from the endoplasmic reticulum membrane Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Broad-spectrum antiviral agents: secreted phospholipase A(2) targets viral envelope lipid bilayers derived from the endoplasmic reticulum membrane
Creator	Kohara, Michinori Chen, Ming Terada, Yutaka Noda, Takeshi Kamitani, Wataru Hotta, Hak Koyanagi, Yoshio Sato, Kei Deng, Lin Aoki-Utsubo, Chie Hijikata, Makoto Kameoka, Masanori Shindo, Keiko
topic	covid:b894fde1276ea66d0eef9ecf55b025adc58f105d#this
source	Medline; PMC
abstract	Hepatitis C virus (HCV), dengue virus (DENV) and Japanese encephalitis virus (JEV) belong to the family Flaviviridae. Their viral particles have the envelope composed of viral proteins and a lipid bilayer acquired from budding through the endoplasmic reticulum (ER). The phospholipid content of the ER membrane differs from that of the plasma membrane (PM). The phospholipase A(2) (PLA(2)) superfamily consists of a large number of members that specifically catalyse the hydrolysis of phospholipids at a particular position. Here we show that the CM-II isoform of secreted PLA(2) obtained from Naja mossambica mossambica snake venom (CM-II-sPLA(2)) possesses potent virucidal (neutralising) activity against HCV, DENV and JEV, with 50% inhibitory concentrations (IC(50)) of 0.036, 0.31 and 1.34 ng/ml, respectively. In contrast, the IC(50) values of CM-II-sPLA(2) against viruses that bud through the PM (Sindbis virus, influenza virus and Sendai virus) or trans-Golgi network (TGN) (herpes simplex virus) were >10,000 ng/ml. Moreover, the 50% cytotoxic (CC(50)) and haemolytic (HC(50)) concentrations of CM-II-sPLA(2) were >10,000 ng/ml, implying that CM-II-sPLA(2) did not significantly damage the PM. These results suggest that CM-II-sPLA(2) and its derivatives are good candidates for the development of broad-spectrum antiviral drugs that target viral envelope lipid bilayers derived from the ER membrane.
has issue date	2017-11-21(xsd:dateTime)
bibo:doi	10.1038/s41598-017-16130-w
bibo:pmid	29162867
has license	cc-by
sha1sum (hex)	b894fde1276ea66d0eef9ecf55b025adc58f105d
schema:url	https://doi.org/10.1038/s41598-017-16130-w
resource representing a document's title	Broad-spectrum antiviral agents: secreted phospholipase A(2) targets viral envelope lipid bilayers derived from the endoplasmic reticulum membrane
has PubMed Central identifier	PMC5698466
has PubMed identifier	29162867
schema:publication	Sci Rep
resource representing a document's body	covid:b894fde1276ea66d0eef9ecf55b025adc58f105d#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/b894fde1276ea66d0eef9ecf55b025adc58f105d
is schema:about of	named entity 'catalyse' named entity 'Here' named entity 'TGN' named entity 'candidates' named entity 'endoplasmic reticulum' named entity 'OPEN' named entity 'POSSESSES' named entity 'VALUES' named entity 'CYTOTOXIC' named entity 'OBTAINED' named entity '28PM' named entity 'CONTRAST' named entity 'ANTIVIRAL AGENTS' named entity 'HERE' named entity 'VIRUSES' named entity 'PLA' named entity 'ER MEMBRANE' named entity 'PHOSPHOLIPASE A 2' named entity 'SUGGEST' named entity 'BUD' named entity 'DAMAGE' named entity '0.31' named entity 'HAEMOLYTIC' named entity 'CONTENT' named entity 'SECRETED' named entity 'PHOSPHOLIPID' named entity 'ISOFORM' named entity 'ENDOPLASMIC RETICULUM MEMBRANE' named entity 'SECRETED' named entity 'SPECTRUM' named entity 'OPEN' named entity 'BROAD' named entity 'VIRAL ENVELOPE' named entity 'ACTIVITY' named entity 'LARGE' named entity 'INHIBITORY' named entity 'CATALYSE' named entity 'NUMBER OF' named entity 'SNAKE VENOM' named entity 'RESULTS' named entity 'THESE' named entity 'POSITION' named entity 'SPLA' named entity 'ANTIVIRAL DRUGS' named entity 'HYDROLYSIS' named entity '036' named entity 'MEMBERS' named entity 'HCV' named entity 'GOOD' named entity 'DERIVED' named entity 'SIMPLEX' named entity 'SENDAI VIRUS' named entity 'TRANS-GOLGI NETWORK' named entity 'PHOSPHOLIPIDS' named entity 'VIRUS' named entity 'DID' named entity 'SUPERFAMILY' named entity 'PARTICULAR' named entity '50%' named entity 'TARGETS' named entity 'DERIVED' named entity 'INFLUENZA VIRUS' named entity 'DEVELOPMENT' named entity 'VIRAL ENVELOPE' named entity 'TARGET' named entity 'NAJA MOSSAMBICA MOSSAMBICA' named entity 'PHOSPHOLIPASE A 2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software